Clinical Study

3000-03-005/Engot-Ov44- A Randomized, Double-Blind, Phase 3 Comparison Of Platinum-Based Therapy With Tsr-042 And Niraparib Versus Standard Of Care Platinum-Based Therapy As First-Line Treatment Of Stage III Or Iv Nonmucinous Epithelial Ovarian Cancer.

Posted Date: Oct 10, 2019

  • Investigator: Thomas Herzog
  • Specialties: Cancer, Oncology, Ovarian Cancer
  • Type of Study: Drug

The goal of this study is to compare the PFS of patients with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to SOC platinum-based therapy


To Be Eligible: >18 Years Of Age, Nonpregnant/Nonbreastfeeding, Confirmed High Grade Ovarian Cancer, No Active Cardiac Disease Or Cns Metastases, No Other Cancers Within 5 Years.


Ovarian Cancer, Oncology

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.